Literature DB >> 19691026

CO(2) laser therapy in Tis and T1 glottic cancer: indications and results.

Lucio Rucci1, Paolo Romagnoli, Jacopo Scala.   

Abstract

BACKGROUND: Laser cordectomy for glottic cancer is still hampered by recurrence, which is more frequent upon anterior commissure (AC) involvement. Analysis of results may be a step to improve the efficacy of this therapy for early glottic cancer.
METHODS: In all, 81 patients who underwent surgery with CO(2) laser for Tis and T1, AC0 to AC2 glottic carcinoma were followed up to 55 months.
RESULTS: The incidence of recurrence increased significantly with T and AC classifications. The disease-free interval decreased with increasing T and AC classifications and with increasing severity of histology, but only the AC classification appeared significant. Recurrences occurred in 5 of 35 patients upon type I and type II cordectomy, in 16 of 24 patients upon type V cordectomy, and never upon type III and IV cordectomy.
CONCLUSIONS: Type I to type IV cordectomy, when indicated, can achieve radical treatment of most T1 glottic cancer. Type V cordectomy requires that any suspicion of cartilage invasion, even microscopic, be excluded.

Entities:  

Mesh:

Year:  2010        PMID: 19691026     DOI: 10.1002/hed.21200

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  9 in total

1.  Radiological tumor thickness as a risk factor for local recurrence in early glottic cancer treated with laser cordectomy.

Authors:  Ho-Jin Son; Yoon Se Lee; Ja Yoon Ku; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-02       Impact factor: 2.503

2.  Impact of resection margin status on oncological outcomes after CO2 laser cordectomy.

Authors:  P Aluffi Valletti; F Taranto; A Chiesa; F Pia; G Valente
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-05-22       Impact factor: 2.124

3.  Adverse histopathological findings in glottic cancer with anterior commissure involvement.

Authors:  Małgorzata Leszczyńska; Maciej Tokarski; Donata Jarmołowska-Jurczyszyn; Paweł Kosikowski; Witold Szyfter; Małgorzata Wierzbicka
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-21       Impact factor: 2.503

4.  Oncological Outcomes Following Transoral CO2 Laser Microsurgery for T1 Glottic Cancer.

Authors:  Ankur Batra; A Goyal; M Goyal; S Goel
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-05-14

5.  Comparison of CT and MRI in Diagnosis of Laryngeal Carcinoma with Anterior Vocal Commissure Involvement.

Authors:  Jian-Hui Wu; Jing Zhao; Zeng-Hong Li; Wei-Qiang Yang; Qi-Hong Liu; Zhi-Yun Yang; Bing Liao; Xiao-Ling Li; Bin Wang; Hao Qin; Jie Luo; Ke-Xing Lv; Wei-Ping Wen; Wen-Bin Lei
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

6.  Does Laser Surgery Interfere with Optical Nerve Identification in Maxillofacial Hard and Soft Tissue?--An Experimental Ex Vivo Study.

Authors:  Bastian Bergauer; Christian Knipfer; Andreas Amann; Maximilian Rohde; Katja Tangermann-Gerk; Werner Adler; Michael Schmidt; Emeka Nkenke; Florian Stelzle
Journal:  Sensors (Basel)       Date:  2015-10-01       Impact factor: 3.576

Review 7.  Involvement of the Anterior Commissure in Early Glottic Cancer (Tis-T2): A Review of the Literature.

Authors:  Martine Hendriksma; Elisabeth V Sjögren
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

Review 8.  European Laryngological Society position paper on laryngeal dysplasia Part II: diagnosis, treatment, and follow-up.

Authors:  Hans Edmund Eckel; Ricard Simo; Miquel Quer; Edward Odell; Vinidh Paleri; Jens Peter Klussmann; Marc Remacle; Elisabeth Sjögren; Cesare Piazza
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-14       Impact factor: 2.503

9.  Middle frontal horizontal partial laryngectomy (MFHPL): a treatment for stage T1b squamous cell carcinoma of the glottic larynx involving anterior vocal commissure.

Authors:  Wen-bin Lei; Ai-yun Jiang; Li-ping Chai; Xiao-lin Zhu; Zhang-feng Wang; Yi-hui Wen; Zhen-zhong Su; Wei-ping Wen
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.